In this trial of preliminary issues, Zacaroli J held that when assessing the damages payable to multiple claimants under cross-undertakings given in respect of various interim injunctions and orders (and for unjustified threats of patent infringement), a single set of counterfactual assumptions should apply to all inquiry claimants, where those claimants operate in the same, largely finite, market. The decision is the latest in a long line of judgments concerning Pfizer’s pregabalin product, Lyrica®.
Pfizer held the marketing authorisation for pregabalin (branded Lyrica®) and Warner-Lambert (…
Cambridge, UK, 07 September 2021– Arecor Therapeutics plc, the biopharmaceutical group which is advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation agreement with Intas Pharmaceuticals Ltd (“Intas”).
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated product for Intas. The new product formulation supports improved usability for the patient compared to current marketed products and in particular facilitates home use outside of a healthcare environment. Intas will…
NORWICH, UK – 07 September 2021: Leaf Expression Systems (Leaf), a biotechnology company specialising in plant-based expression, today announced the launch of SupraVecTM, Leaf’s new proprietary vector-based expression technology for the rapid production of proteins, vaccines and complex biomolecules within the leaf tissue of plants.
SupraVecTM is a plant transient expression system designed with novel expression components to optimise yields. The expression technology delivers a three-fold improvement in the yield compared to Leaf’s previous pEAQ-HT system, also known as Hypertrans® (figure 1…
Today marks the official opening of our operations in Dublin, and our 29th office worldwide.
Plans to open in Ireland were announced earlier this year with the appointment of the firm's latest partner hires.
Opening in Dublin presents new opportunities for clients including large organisations, start-ups, investors and entrepreneurs across Europe and the US, especially in life sciences and healthcare and technology sectors, which the firm is recognised for.
Adam Griffiths, who was previously a member of the firm's Private Equity team and relocated to Ireland in 2017, has returned to…
Babraham, 06 September 2021: Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.The name change more clearly reflects the activity of the organisation and is also in response to the refreshed and ambitious vision for the Campus announced in May this year.Jo Parfrey, Chair of the Babraham Research Campus Board, says: “The new identity signals our ongoing focus on the world-class bioscience Campus at the…
The UK Court of Appeal has reviewed the law on insufficiency and its application to claims with both structural and functional limitations. In doing so the court has explained how the concepts of plausibility and undue burden should be applied when assessing the sufficiency of claims of this type, in particular to the requirement that it must be possible to perform the invention across the breadth of the claim.
The appeal concerned six patents belonging to FibroGen, which had been divided into two “families”. The court had to consider issues of obviousness and infringement, as well as…
Germany has finally ratified the Unified Patent Court Agreement, its Constitutional Court having rejected two applications for a preliminary injunction to prevent ratification. This removes a significant hurdle to the commencement of the Unified Patent Court (UPC) system but that is not to say that it will start any time soon. The UPC preparatory committee, which consists of representatives the countries which signed the UPC Agreement back in 2013, estimates that the UPC will start operating in mid-2022. It is certainly unlikely that the UPC will start its operations before then but it may…
The Institute of Cancer Research, London, has earned the most staff-adjusted invention income of any UK higher education institution for the eighth year in a row.
A higher education institution’s invention income is a key marker of its success at commercialising its research for public benefit through collaboration with industry.
The ICR’s analysis of newly released figures from the Higher Education and Statistics Authority (HESA) show that we received the most income from intellectual property, per member of academic staff, of any higher education institution in the UK in the 2019-20…
We have advised leading European 10-minute grocery delivery platform Dija on its successful exit to dominant US player, Gopuff. Having initially advised the business on its $20 million seed round in December 2020, we provided support through the company's rapid growth and significant European expansion ahead of guiding it through its exit.
Grocery delivery start-ups have shot to prominence in the UK and elsewhere during the COVID-19 pandemic as customers have opted to order their essentials from the safety of their own homes through online platforms. Founded by delivery industry leaders…